A clinical trial involving oxytocin was updated on September 17, 2026. The study, titled "Intravenous Papaverine for Term Prelabor Rupture of Membranes," is registered under ClinicalTrials.gov identifier NCT07826533.
The trial is listed with a phase designation of NA and a current status of recruiting. This means the study is actively enrolling participants as of the date listed in the registry.
No results have been posted for this trial at this time. The registry entry reflects only the trial's design status and enrollment stage, not any outcomes or efficacy data. As such, no conclusions about safety or effectiveness can be drawn from this update.
Details about the study protocol, eligibility criteria, and objectives can be found in the full registration record. Readers interested in oxytocin's broader clinical and regulatory background can consult the compound overview for additional context.